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Ha-Ras and Ki-Ras have different distributions across
plasma membrane microdomains. The Ras C-terminal
anchors are primarily responsible for membrane micro-
localization, but recent work has shown that the inter-
action of Ha-Ras with lipid rafts is modulated by GTP
loading via a mechanism that requires the hypervari-
able region (HVR). We have now identified two regions
in the HVR linker domain that regulate Ha-Ras raft
association. Release of activated Ha-Ras from lipid rafts
is blocked by deleting amino acids 173–179 or 166–172.
Alanine replacement of amino acids 173–179 but not
166–172 restores wild type micro-localization, indicat-
ing that specific N-terminal sequences of the linker do-
main operate in concert with a more C-terminal spacer
domain to regulate Ha-Ras raft association. Mutations
in the linker domain that confine activated Ha-RasG12V
to lipid rafts abrogate Raf-1, phosphoinositide 3-kinase,
and Akt activation and inhibit PC12 cell differentiation.
N-Myristoylation also prevents the release of activated
Ha-Ras from lipid rafts and inhibits Raf-1 activation.
These results demonstrate that the correct modulation
of Ha-Ras lateral segregation is critical for downstream
signaling. Mutations in the linker domain also suppress
the dominant negative phenotype of Ha-RasS17N, indi-
cating that HVR sequences are essential for efficient
interaction of Ha-Ras with exchange factors in intact
cells.
The guanine nucleotide-binding protein Ras acts as a molec-
ular switch connecting extracellular signals with a complex
network of intracellular signal transduction pathways that
mediate a variety of cellular responses including proliferation
and differentiation (1, 2). The three mammalian ras genes
encode for four proteins of 188 and 189 amino acids (Ha-Ras,
N-Ras, Ki-RasA, Ki-RasB) that are identical over the N-termi-
nal 85 amino acids and 90% homologous over the next 80
residues. These N-terminal 165 residues are sufficient for bind-
ing guanine nucleotides and interacting with effector and ex-
change factor proteins in vitro. The divergence between the Ras
isoforms is largely confined to the final 23 and 24 C-terminal
amino acids, the so-called hypervariable region (HVR)1 in
which less than 10–15% of residues are identical between any
pair of Ras proteins.
The localization of Ras to the inner surface of the plasma
membrane is essential for its biological activity (3). The two
signals responsible for the correct plasma membrane localiza-
tion of Ras are contained in the Ras HVR. The first signal
sequence, common to all Ras proteins, is the C-terminal CAAX
box (in which A  aliphatic amino acid and X  serine or
methionine) that is sequentially farnesylated, -AAX proteo-
lyzed, and carboxyl-methylated (3–6). This series of posttrans-
lational modifications is completed on the cytoplasmic surface
of the endoplasmic reticulum. The second signal comprises
palmitoylation of two upstream cysteines (Cys181 and Cys184)
in Ha-Ras, one cysteine (Cys181) in N-Ras, and a polybasic
sequence of multiple lysines (Lys175–180) in Ki-Ras2 (7, 8).
These targeting signals direct the trafficking of Ras to the cell
surface via alternative routes. After palmitoylation, probably
also in the endoplasmic reticulum, Ha- and N-Ras traffic
through the classical exocytic pathway via the Golgi to the
plasma membrane (9, 10). Ki-Ras in contrast bypasses the
Golgi and reaches the plasma membrane by an unknown mech-
anism that may involve transport or simple diffusion (9–13).
For convenience we refer to the sequences of the Ras HVR that
are involved in trafficking and plasma membrane attachment
as the membrane-targeting domain and the remainder of the
Ras HVR as the linker domain.
A number of studies have shown that the membrane-target-
ing domains localize Ha-Ras and Ki-Ras to different microdo-
mains of the plasma membrane. A dominant negative mutant
of caveolin, CavDGV, which blocks delivery of cholesterol to the
plasma membrane (14), completely blocks Ha-Ras-dependent
Raf activation but does not affect Ki-Ras signaling (15). The
inhibition is reversed by repleting plasma membranes with
cholesterol. In addition, chemically depleting plasma mem-
brane cholesterol with cyclodextrin selectively inhibits Ha-Ras
but not Ki-Ras function (15). Taken together, these data sug-
gest that Ha-Ras but not Ki-Ras function is dependent on the
integrity of lipid rafts in the plasma membrane. More recently
we used electron and fluorescent microscopy coupled with bio-
chemical fractionation to examine the plasma membrane mi-
crodomain distributions of Ha- and Ki-Ras (16). The results
were unexpected but clear. The C-terminal minimal mem-
brane-targeting sequences of Ha-Ras localize GFP to caveolae
and lipid rafts, whereas the equivalent targeting signals for
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Ki-Ras do not. Wild type GDP-bound Ha-Ras is distributed
equally between lipid raft and non-raft membrane, but consti-
tutively activated GTP-bound Ha-Ras is almost completely ex-
cluded from lipid rafts and caveolae. In contrast, GDP- and
GTP-loaded Ki-Ras are both absent from caveolae and co-frac-
tionate with markers of disordered plasma membrane. The
data suggest that Ha-Ras is in a GTP-regulated equilibrium
between lipid rafts and non-raft plasma membrane (16, 17).
Interestingly, the Ha-Ras linker domain is necessary for the
GTP-dependent release of Ha-Ras from lipid rafts and for bio-
logical activity (16). Other studies have also shown that ma-
nipulation of the C-terminal membrane anchor of Ha-Ras de-
creases Ras biological activity in NIH3T3 and PC12 cells by
changing effector pathway utilization (18, 19). Together these
observations demonstrate that the integrity of the HVR is
essential for normal Ha-Ras signaling.
The aim of the present study was to investigate in more
detail the role of the HVR linker domain in Ha-Ras function. In
particular we wanted to establish what structural features
and/or specific sequences in the linker domain contribute to the
modulation of Ha-Ras raft association and to examine whether
raft association alone determines the efficiency with which
Ha-Ras interacts with specific effectors and activators. These
are important questions because differential distribution of
Ras isoforms, exchange factors, effectors, and effector co-acti-
vators across plasma membrane microdomains is the simplest
mechanism that can account for the increasing number of bio-
logical and in vivo biochemical differences that are being iden-
tified between Ha-, Ki-, and N-Ras.
EXPERIMENTAL PROCEDURES
Plasmids—Ha-RasG12V cDNA sequences encoding His166 though
Asn172 or Pro173 though Pro179 were deleted or replaced with polyala-
nine using oligonucleotide-directed mutagenesis to generate H1-
G12V, H1ala-G12V, H2-G12V, and H2ala-G12V, respectively. Mu-
tated cDNAs were fully sequenced and cloned into the expression vector
pEXV3, Gly12, and Asn17 versions of the HVR mutants were constructed
by recombination with pEXV-Ha-Ras and pEXV-Ha-RasS17N, respec-
tively. EXV-Hhvr-G12V and EXV-Mys-Ha-Ras have been described
previously (16, 20).
Cell Culture and Transfection—BHK cells were cultured at 37 °C in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10%
bovine calf serum. Cells were plated onto 10-cm plates at 60% conflu-
ence and transfected with 5–10 g of expression plasmid using Lipo-
fectAMINE (Invitrogen) according to the manufacturer’s instructions.
After 5 h of incubation with the transfection mix, medium containing
20% calf serum was added for an overnight incubation. Next day, the
cells were incubated for 6 h in serum-free medium and then processed.
PC12 cells were cultured in DMEM supplemented with 5% horse se-
rum, 10% calf serum, and 2 mM L-glutamine and were transfected using
LipofectAMINE. 16 h after lipofection, the cells were returned to stand-
ard PC12 maintenance medium and were incubated a further 48 h prior
to processing for confocal microscopy. COS cells were cultured in
DMEM supplemented with 10% bovine calf serum at 37 °C. The cells
were electroporated with expression plasmids, and after 48 h, they were
serum-starved for 16 h before being harvested for the GTP-loading
assays.
Cell Fractionation—Transfected BHK and COS cells were washed
with cold phosphate-buffered saline, scraped on ice into 0.3 ml of Buffer
A (10 mM Tris-Cl, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 1 mM dithiothreitol,
100 M NaVO4, 25 mM NaF, 10 g/ml leupeptin, and 10 g/ml aproti-
nin), and homogenized through a 23-gauge needle. Post-nuclear super-
natants obtained by low speed centrifugation were spun at 100,000  g
at 4 °C for 30 min, and the soluble fraction (S100), which contains
cytosolic proteins, was collected. The sedimented fraction (P100), which
contains cellular membranes, was rinsed and resuspended in 100 l of
Buffer A.
Western Blotting—Protein content was measured by the Bradford
reaction. 20 g each of S100 and P100 fraction was separated in 10 and
12% SDS-polyacrylamide gels and transferred to polyvinylidene diflu-
oride membranes. Western blotting was performed using the following
antibodies: Ras (Y13–259), Phospho-MEK1/2 (Ser217/221) (No. 9121 Cell
Signaling), Phospho-p44/42 MAP kinase (Thr202/Tyr204) (No. 9106S,
Cell Signaling), or Phospho-Akt (Ser473) (No. 9271S, Cell Signaling).
Western blots were developed using horseradish peroxidase-conjugated
secondary antibodies and ECL (SuperSignal; Pierce) and quantified by
phosphorimaging with a CH-screen (Bio-Rad).
Confocal Microscopy—Transfected PC12 or BHK cells were washed
with phosphate-buffered saline and fixed with 4% paraformaldehyde for
30 min at room temperature. Indirect anti-Ras immunofluorescence
using Y13–238 and FITC-coupled anti-rat secondary antisera was per-
formed as described previously (10). Coverslips were mounted in
mowiol for confocal microscopy.
Raf-1 Kinase Assays—Raf activity was measured in a coupled MEK/
ERK assay with myelin basic protein phosphorylation as readout ex-
actly as described (21).
Sucrose Gradients—Cell membranes were resolved in bottom-loaded
continuous sucrose gradients exactly as described (16, 22).
Phosphoinositide 3-Kinase (PI3K) Assays—Transfected BHK cells
were serum-starved for 6 h, harvested, and fractionated into S100 and
P100 fractions. 400 g of each P100 fraction was collected by centrifug-
ing at 100,000  g at 4 °C for 30 min. The membrane pellets were
resuspended by sonication in 100 l of lysis buffer (50 mM HEPES, pH
7.5, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM MgCl2, 1 mM
EGTA, 10 mM Na4P2O7, 100 mM sodium fluoride, 10 g/ml aprotinin, 10
g/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride, and 1 mM
NaVO4), and after a 15-min incubation on ice, they were recentrifuged
at 100,000 g at 4 °C for 20 min. The supernatants were discarded, and
the new pellets were resuspended by sonication in 25 l of 2 kinase
buffer (40 mM Tris-Cl, pH 7.6, 150 mM NaCl, and 20 mM MgCl2). 25 l
of kinase mix (phosphatidylinositol, 200 g/ml sonicated in 20 mM
HEPES, pH 7.5, 20 M ATP, 200 M adenosine, and 10 Ci of
[-32P]ATP (6,000 Ci/mmol)) was added, and kinase reactions were
carried out for 20 min at 25 °C in a vortexing heating block. Reactions
were stopped with 100 l of 1 N HCl, and phospholipids were extracted
once with 200 l of CHCl3:MeOH (1:1) and once with 160 l of 1 N
HCl:MeOH (1:1). Phosphorylated lipid products were resolved on ox-
alate-impregnated Silica60 plates (Merck) using CHCl3:MeOH:4 M
NH4OH (9:7:2) as solvent and visualized and quantified by phosphor-
imaging with a BI screen (Bio-Rad).
Triton Solubility Assay—Cells were transfected, harvested, and frac-
tionated as described above. Aliquots of P100 fraction were added to a
dilution range of Triton X-100 in Buffer Q (25 mM Tris-Cl, pH 7.5, 5 mM
MgCl2, and 25 mM KCl) to obtain a final concentration of 0, 0.05, 0.25,
and 0.5% Triton X-100. The samples were then sonicated for 15 s,
incubated on ice for 15 min, sonicated again for 10 s, and centrifuged at
100,000  g for 30 min. The supernatants were discarded, and the
pellets were dissolved in sample buffer, resolved on 15% SDS-polyacryl-
amide gels, and immunoblotted for Ras.
GTP-loading Assays—S100 and P100 fractions were prepared from
COS cells transfected as described above. The P100 fractions were
resuspended in 400 l of lysis buffer (20 mM Tris-Cl, pH 7.5, 150 mM
NaCl, 0.5% Triton X-100, 0.5% sodium deoxycholate, 10 g/ml aproti-
nin, and 1 mM phenylmethylsulfonyl fluoride), sonicated, and then spun
at 14,000 rpm at 4 °C for 5 min, and soluble supernatants were moved
to new tubes. Protein content was measured by the Bradford reaction,
and 120 g of the sample was incubated with 1 ml of binding buffer (50
mM Tris-Cl, pH 7.5, 10 mM MgCl2, 0.5 mg/ml bovine serum albumin, 0.5
mM dithiothreitol, and 100 mM NaCl) and 20 l of GSTRBD K85A
fusion protein (50% suspension  20 g) for 90 min at 4 °C. For details,
see Ref. 23. After washing three times with binding buffer, the final
pellet was resuspended in 20 l of 2 sample buffer, boiled, and loaded
in 15% gels for Western blotting analysis using anti-Ras antibodies. 10
g of the solubilized P100 fraction was also immunoblotted to normalize
for total Ras content. After quantifying the immunoblots in a phospho-
rimaging device, GTP loading was estimated by calculating (RBD-
bound Ras)/(total Ras present in 10 g of solubilized P100 fraction). The
phosphorimaging device units are arbitrary, but our previous compar-
isons of estimating GTP loading using the RBD pull-down assay with
GTP loading measured by 32P labeling, Ras immunoprecipitation, and
TLC have shown that 10 arbitrary units  2% GTP-bound Ras.
Toxicity Assays—BHK cells were transfected with 10 g of S17N-
substituted plasmid plus 0.8 g of pC1 (which carries a G418-selectable
marker). After 5 h, medium containing 20% calf serum was added for
24 h, and then the transfected cells were split between eight 10-cm
plates into medium containing 10% calf serum and 500 g/ml G418.
Cells were maintained for 16 days and then fixed with cold methanol
and stained with 10% Geimsa’s stain, and the colonies were counted.
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RESULTS
Identification of Two Regions within the Ha-Ras HVR Linker
Domain That Regulate Raft Association—Our previous results
showed that deletion of the entire linker domain of Ha-Ras
(166–179) totally confines activated HhvrG12V to lipid rafts
and partially abrogates the ability of HhvrG12V to activate
Raf-1 (16). To further characterize the HVR linker domain, we
constructed four additional mutants of this region. We deleted
amino acids 166–172 or 173–179 from activated Ha-RasG12V,
i.e. the N-terminal or C-terminal amino acids of the linker
domain, to create the mutants H1 and H2, respectively (Fig.
1). In addition, we generated two alanine replacement mutants
by substituting the amino acids 166–172 or 173–179 with an
equivalent number of alanine residues to generate H1ala and
H2ala (Fig. 1). The membrane-targeting domain of the HVR is
left intact in all these constructs, and Fig. 1B shows that as
expected, all of the Ha-Ras HVR-mutated proteins localized
normally to the plasma membrane when expressed in BHK
cells.
We next examined the distribution of the Ha-Ras linker
domain mutants between raft and non-raft membranes. Deter-
gent-free lysates prepared from transiently transfected BHK
cells were fractionated over sucrose gradients. 10 fractions
were collected from the top to the bottom of each gradient, and
the membranes contained in each fraction isolated by centrif-
ugation. Membrane pellets were then analyzed by immunoblot-
ting using anti-Ras antibodies. We have previously extensively
characterized this gradient protocol and shown that lipid raft-
enriched membranes are readily resolved from non-raft mem-
branes (16, 22). Specifically, lipid raft markers are found in the
top 5 fractions of the gradients, which contain light mem-
branes, and non-raft markers are confined to the denser bottom
5 fractions (16, 22).
In accordance with our previous results, more than 80% of
activated Ha-RasG12V was present in the high density frac-
tions (6–9) and was totally excluded from the top fractions of
the gradient (Fig. 2). In contrast, the truncated proteins H1-
G12V and H2-G12V and the alanine-substituted protein
H1ala-G12V fractionated almost exclusively to the lipid raft-
enriched fractions (2–5) as seen previously for HhvrG12V (see
Fig. 2 and Ref. 16). Interestingly, however, the distribution of
the alanine-substituted protein H2ala-G12V more closely re-
sembled that of full-length Ha-RasG12V with a small peak in
lipid raft fractions 2 and 3 and a more major peak in fractions
7–10. One interpretation of these results is that the whole
Ha-Ras linker domain is required for correct lateral segrega-
tion, but although the specific amino acid sequence of 166–172
is critical, residues 173–179 may just operate as an essential
spacer element, the specific sequence of which is not important.
Correlation of Raft Micro-localization with Biochemical Ac-
tivity—To characterize the potential biological implications of
defective membrane micro-localization, we examined the abil-
ity of the HVR mutants to activate downstream effectors. Mem-
brane (P100) fractions from BHK cells transiently transfected
with full-length Ha-RasG12V or the HVR linker domain mu-
tants were normalized for Ras content and assayed for Raf-1
activity using a coupled MEK-ERK assay. Fig. 3, A and B,
shows that the ability of H1-G12V and H2-G12V to activate
Raf-1 was severely compromised compared with that of full-
length Ha-RasG12V. The abrogation of activity was similar to
that seen with HhvrG12V. The ability of H1ala-G12V to
activate Raf-1 was also compromised but not to the same extent
as H1-G12V, H2-G12V, or HhvrG12V (Fig. 3, A and B). In
contrast, the alanine replacement mutant H2ala-G12V acti-
vated Raf-1 as efficiently as full-length Ha-RasG12V (Fig. 3, A
and B). We next examined the levels of activated MEK and
ERK in the S100 fractions of the same lysates by immunoblot-
ting with phospho-specific antisera. Fig. 3A shows that MEK
phosphorylation was significantly compromised only in cells
expressing HhvrG12V. Moreover, levels of phosphorylated
ERK were essentially equivalent in all of the mutant-express-
ing cells. Thus recruitment of Raf to lipid rafts by mislocalized
Ha-Ras compromises activation but also apparently interferes
with the communication between Raf, MEK, and MAPK, per-
haps by preventing appropriate negative feedback within the
kinase cascade.
Membrane fractions were then assayed for endogenous PI3K
activity in an in vitro lipid kinase assay using phosphatidyl-
inositol as substrate. Expression of HhvrG12V, H1-G12V,
and H2-G12V failed to activate PI3K, whereas expression of
H2ala-G12V or full-length Ha-RasG12V generated substan-
tial membrane-associated PI3K activity (Fig. 3, C and D). Ex-
FIG. 1. The Ha-Ras HVR linker domain mutants localize at the
plasma membrane. A, Ha-RasG12V HVR linker domain mutants
H1-G12V and H2-G12V were constructed by deleting Ha-RasG12V
cDNA sequences encoding His166 though Asn172 or Pro173 though Pro179,
respectively. Mutants H1ala-G12V and H2ala-G12V were generated
by replacing the above sequences with polyalanine. The HhvrG12V
mutant consists of a deletion of the entire linker domain of Ha-Ras
(166–179). The membrane-targeting sequences remain intact in these
proteins. B, confocal images of BHK cells transiently expressing Ha-
RasG12V (A), H2-G12V (B), H2ala-G12V (C), H1-G12V (D),
H1ala-G12V (E), and HhvrG12V (F). All Ha-Ras HVR linker domain
mutants localize to the plasma membrane.
FIG. 2. Distribution of Ha-Ras HVR linker domain mutants on
sucrose gradients. Carbonate lysates of cells transiently expressing
Ha-RasG12V or the HVR linker domain mutants were sonicated and
fractionated over sucrose gradients. 10 fractions, numbered from the
top to the bottom of the gradient, were collected. These fractions were
recentrifuged to isolate cell membranes, and the membrane pellets
were immunoblotted for Ras. Note that all HVR linker domain mutants,
except H2ala-G12V, exclusively localize to the lipid raft-containing
fractions (top 5 fractions of the gradient). Full-length Ha-RasG12V and
H2ala-G12V are found predominantly in the non-raft enriched frac-
tions (bottom 5 fractions of the gradient).
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pression of H1ala-G12V generated low PI3K activity in the
majority of our experiments (as shown in Fig. 3C), but in some
experiments, higher levels of PI3K activity were detected. The
reasons for this variability are unclear. To verify the results of
the in vitro lipid kinase data, we therefore assessed the acti-
vation status of Akt in the same cell lysates by quantitative
immunoblotting using phospho-specific antisera. Cells express-
ing HhvrG12V, H1-G12V, H2-G12V, or H1ala-G12V had
low levels of phosphorylated Akt both in cell membranes and in
cytosol consistent with the profile of PI3K activation (Fig. 3E).
H2ala-G12V was the only mutant protein capable of acti-
vating Akt to the same extent as full-length Ha-RasG12V
(Fig. 3E).
Biological Activity of HVR Linker Domain Mutants—To as-
sess the biological activity of the Ha-RasG12V HVR linker
domain mutants, the constructs were tagged with N-terminal
GFP and transfected into PC12 cells. After 48 h, the cell cul-
tures were fixed. The morphology of the cells was compared
with cells expressing full-length Ha-RasG12V that undergo
extensive neurite outgrowth and differentiation and cells ex-
pressing membrane-targeted GFP-tH that do not differentiate
(GFP-tH consists of the C-terminal 10 amino acids of Ha-Ras
cloned onto the C terminus of GFP) (Fig. 4). To quantify the
extent of differentiation, mean neurite length was calculated
from a random sample of 50 cells expressing each Ha-Ras
protein (Fig. 4). Cells expressing HhvrG12V, H1-G12V, or
H2-G12V showed some enlargement of the cell body and in
some cases the formation of very short neurite-like structures,
but the extent of these changes and the complexity of the
differentiation was markedly reduced compared with full-
length Ha-RasG12V (Fig. 4). The alanine-substituted mutant
H1ala-G12V induced slightly more neurite outgrowth than
the cognate-deletion mutant. However, only the differentiation
induced by H2ala-G12V resembled that observed with full-
length Ha-RasG12V. It is clear that the profiles of PC12 differ-
entiation observed in these experiments correlate closely with
the biochemical and raft micro-localization data shown in Figs.
2 and 3.
N-Myristoylation Confines Activated Ha-Ras to Lipid Rafts
and Abrogates Raf-1 Activation—The simplest conclusion to be
drawn from the preceding experiments is that preventing the
access of activated Ha-Ras to the disordered plasma membrane
blocks biological activity. An alternative interpretation is that
the linker domain modulates raft association but also directly
interacts with plasma membrane-localized Raf-1 and PI3K. We
therefore used another mechanism to confine activated Ha-Ras
to lipid rafts that did not involve mutating the HVR linker
domain. We have previously shown that the addition of an
N-myristoylation signal to Ha-RasG12V does not interfere with
plasma membrane localization. However, sucrose gradient
analysis showed that Mys-Ha-RasG12V is extensively localized
to lipid rafts (Fig. 5A; compare with Fig. 2). Consistent with
this observation, assays of raft association based on detergent
insolubility showed that membrane-associated Mys-Ha-
FIG. 3. Biochemical activities of Ha-Ras HVR linker mutants.
BHK cells expressing Ha-RasG12V or HVR linker domain mutants or
transfected with empty EXV vector as control were fractionated. P100
fractions were immunoblotted for Ras and assayed for Raf activity
using a coupled MEK-ERK assay (A). An autoradiograph of a repre-
sentative Raf assay is shown as phosphorylated myelin basic protein
(P-MBP). S100 fractions from the same cells were then immunoblotted
for activated MEK (P-MEK) and Erk (P-Erk) with phospho-specific
antisera. The graph shows mean Raf activity ( S.E., n 3) in arbitrary
phosphorimaging device units (B). Differences between each mean and
the Ha-RasG12V control were examined in t tests; significant differ-
ences are indicated by * (p  0.05) or ** (p  0.01). PI3K activity in the
cell membranes was measured in an in vitro lipid kinase assay using
phosphatidylinositol as substrate (C). The phosphorylated products
were resolved by TLC, and the position of PI-3P is marked with an
arrow. PI3K assays were quantified by phosphorimaging the TLC
plates. (D) The graph shows mean relative PI3K ( S.E.) calculated
from 3 or 4 independent experiments. Levels of activated Akt in P100
and S100 fractions of the same cell lysates were analyzed by immuno-
blotting with a phospho-specific antisera (E).
FIG. 4. Biological activity of Ha-Ras HVR linker mutants. PC12
cells were transfected with Ha-RasG12V or HVR linker domain mu-
tants tagged with N-terminal GFP. As a negative control, PC12 cells
were transfected with GFP-tH. After 48 h, the morphology of the ex-
pressing cells was assessed by confocal microscopy. The upper panel
shows a representative field of PC12 cells expressing each Ras protein.
The lower panel is a quantification of the extent of neurite outgrowth.
The graph shows mean dendrite length per cell ( S.E.) calculated from
measurements on 48–69 cells expressing each Ras protein. Measure-
ments were made using NIH Image software on confocal images of 7 or
8 random fields of cells expressing each Ras protein collected from 3
independent transfections.
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RasG12V was resistant to extraction in 0.05% Triton X-100,
whereas 75% of Ha-RasG12V was solubilized (Fig. 5B). Similar
to the results obtained with the HVR mutants, raft-associated
Mys-Ha-RasG12V was a weaker activator of Raf-1 than Ha-
RasG12V (Fig. 5C).
The Interaction of Plasma Membrane-associated Ha-Ras
with Exchange Factors Is Altered by Mutations in the HVR
Linker Domain—The S17N mutation results in a Ras protein
that forms an irreversible complex with RasGEFs and renders
RasS17N dominant negative for cell growth (24). To investigate
whether the HVR influences the ability of Ha-Ras to interact
with RasGEFs in vivo, we introduced the S17N mutation into
the Ha-Ras linker domain mutants and assayed them for
growth inhibition. BHK cells were co-transfected with S17N-
substituted Ha-Ras constructs and pC1, a neomycin resistance
plasmid, and selected for 16 days in G418. The number of
surviving cells was then compared with control plates trans-
fected with an equivalent amount of empty Ras expression
vector. Fig. 6A shows that the growth inhibitory phenotype of
Ha-RasS17N is markedly reduced in the context of all five
linker domain deletions or alanine substitutions. This result
strongly suggests that efficient interaction between membrane-
associated Ha-Ras and RasGEFs requires an intact HVR linker
domain.
To extend this analysis, we assessed directly whether the
linker domain influences the sensitivity of Ha-Ras to activation
by a specific exchange factor, Sos1. COS cells were transfected
with Ha-Ras or the HVR linker domain mutants, all wild type
at codon 12, with or without mSos1. The amount of GTP-loaded
Ha-Ras protein in the membrane fraction was then determined
by a GSTRBD pull-down assay. The basal levels of GTP load-
ing of H2 and H2ala were significantly lower (p 0.01) than
wild type Ha-Ras (Fig. 6B). Similarly, the levels of GTP loading
of H2 and H2ala in cells co-expressing an equivalent low
level of mSos1 were all significantly lower (p  0.05) than the
GTP loading of full-length Ha-Ras (Fig. 6B). These results are
what would be expected if the efficiency of interaction of H2
and H2ala with Sos1 is compromised as suggested by the
S17N toxicity assays. The basal and Sos1-stimulated GTP load-
ing of Hhvr were also consistently lower than full-length
Ha-Ras, but these differences were not statistically significant
(p 0.1). Intriguingly, however, the basal and Sos1-stimulated
GTP loading of H1 and H1ala were significantly greater (p
0.05 or p  0.01) than that seen with the corresponding wild
type Ha-Ras control (Fig. 6B).
DISCUSSION
Numerous studies published over the last few years have
challenged the view that the highly homologous Ha-, Ki-, and
N-Ras are functionally redundant. Transgenic experiments
have shown that only Ki-Ras is required for normal mouse
development (25–27), whereas primary cell culture experi-
FIG. 5. N-Myristoylation confines activated Ha-Ras to lipid
rafts and abrogates Raf-1 activation. Carbonate lysates of cells
transiently expressing Mys-Ha-RasG12V were fractionated over su-
crose gradients as in Fig. 2 (A). In contrast to non-myristoylated Ha-
RasG12V, Mys-Ha-RasG12V localizes exclusively to the lipid raft-con-
taining fractions (compare with Fig. 2). P100 fractions of COS cells
transfected with Ha-RasG12V or with Mys-Ha-Ras were solubilized in
0, 0.05, 0.25, or 0.5% Triton X-100 (B). P100 fractions were then reiso-
lated by centrifugation and immunoblotted for Ras. The graph shows
the mean fraction (%) of Ras ( S.E., n  3) that was detergent-
insoluble in each concentration of Triton X-100. P100 fractions from
COS cells transfected with Ha-RasG12V or with Mys-Ha-RasG12V
were assayed for Raf kinase activity in a coupled MEK-ERK assay (C).
The graph shows mean relative Raf activity ( S.E.), normalized for
Ras expression, that was calculated from 4 independent experiments.
FIG. 6. Mutation of the Ha-Ras linker domain disrupts inter-
actions with RasGEFs. An S17N mutation was introduced into the
Ha-Ras linker domain mutants (A). BHK cells were co-transfected with
10 g of each S17N expression plasmid together with 0.8 g of pC1 as
selectable marker. Transfections were selected in G418 for 16 days, and
the number of colonies was determined after Giemsa staining. The
number of surviving cells is expressed as a percentage of the controls
that were co-transfected with 10 g of empty Ras expression vector
(EXV) and 0.8 g of pC1. The results shown are the mean ( S.E.) of
three independent experiments. COS cells were transfected with ex-
pression plasmids for wild type Ha-Ras or Ha-Ras linker domain mu-
tants that were wild type (Gly) at codon 12 (B). COS cells were also
co-transfected with the same Ha-Ras plasmids and 2 g of mSos1
expression plasmid. Equivalent expression of Sos1 was verified by im-
munoblotting (not shown). Basal levels and Sos1-stimulated GTP load-
ing of membrane-associated Ha-Ras was then determined using a
GSTRBD pull-down assay. The graph shows results (in arbitrary phos-
phorimaging units) from 3 independent experiments in which each
GTP-loading assay was performed in duplicate, and the bars show the
mean ( S.E., n  6). The statistical significance of the results was
assessed using t tests. The wild type basal GTP level was compared
with that of each mutant, and the wild type Sos1-stimulated GTP level
was compared with that of each mutant. Significant differences are
indicated by * (p  0.05) or ** (p  0.01). The degrees of freedom for
each t test were reduced from 10 to 5 because of the multiple (i.e. 5)
comparisons made with each control mean.
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ments have shown that N-Ras may have a specific role in
suppressing apoptosis (28). In addition, different Ras isoforms
transform established fibroblasts with varying efficiencies and
exhibit different phenotypes in cell motility and migration as-
says (29, 30). These biological differences must result from
different signal outputs from activated Ha-, N- or Ki-Ras
and/or different sensitivities to activation by exchange factors.
All three Ras proteins share a common set of GEFs and effec-
tors, yet there are marked quantitative differences in their use
of these interacting proteins in intact cells. For example, Ras-
GRF1 activates Ha-Ras more efficiently than N- or Ki-Ras (31),
RasGRP2 activates N- and Ki-Ras but not Ha-Ras (23), and
mSos1 activates Ras in the hierarchy Ha  N Ki-Ras.3 Also,
with respect to effector interactions, Ki-Ras is more potent than
Ha-Ras at activating Raf-1 and Rac1, whereas Ha-Ras is more
potent than Ki-Ras at activating PI3K (29–32). Analysis of
Ha/Ki-Ras chimeras has shown that the biological phenotype of
the chimeric protein correlates with the origin of the C-termi-
nal HVR (30). Others have shown that perturbing the mecha-
nism of interaction of the C-terminal anchor with the plasma
membrane alters the efficiency with which Ha-Ras activates
Raf-1 and PI3K (18, 19). These data, taken together with our
observations that the Ha-Ras and Ki-Ras C-terminal anchors
target to different plasma membrane microdomains, lead to the
attractive hypothesis that biochemical and biological differ-
ences between the Ras isoforms are due to differences in
plasma membrane micro-localization.
The interaction of full-length Ha-Ras with lipid rafts is reg-
ulated by GTP loading and is dependent on sequences in the
HVR linker domain (16). In the present study, we investigated
whether the linker domain modulates Ha-Ras function by di-
rectly altering interactions with effectors and GEFs and/or
indirectly by altering plasma membrane micro-localization.
The deletion analysis shows that, with respect to regulating
raft interactions, there are two distinct requirements of the
linker domain. Amino acids 173–179 operate as a spacer ele-
ment because their replacement with alanine residues in
H2ala allowed access to the disordered plasma membrane
and restored the diminished effector function of H2 back to
wild type levels. In contrast, deletion of amino acids 166–172
compromised the normal raft/non-raft equilibrium and effector
function of Ha-Ras, and this was not restored by alanine re-
placement. This suggests that the specific sequence of 166–172
rather than its length is important for regulating Ha-Ras raft
association and function.
In Ki-Ras, the sequence corresponding to amino acids 173–179
is taken up by the polybasic domain. This sequence interacts
electrostatically with the negatively charged plasma membrane
and is in close proximity with the inner leaflet; it is therefore
tempting to speculate that the catalytic domains of Ha-Ras may
be spaced further away from the inner surface of the plasma
membrane than are those of Ki-Ras. Interestingly a recent anal-
ysis of the HVR of Ki-RasG12V described two constructs in which
a short or long polybasic domain plus a CAAX motif was ap-
pended directly onto the N-terminal 165 amino acids. Both pro-
teins had a much lower transforming activity than full-length
Ki-RasG12V despite both being efficiently localized to the plasma
membrane (33). These mutant Ki-Ras constructs effectively have
a deletion of the linker domain sequence 166–174; thus specific
residues in this region of both Ha- and Ki-Ras appear to be
essential for the effector interactions of both Ras proteins. It has
not yet been determined, however, whether the microdomain
localization of Ki-Ras is altered by deletion of these sequences, as
is the case for Ha-Ras.
Our data show a clear correlation between confinement of
Ha-Ras to lipid rafts and defective effector function as meas-
ured in Raf-1 and PI3K assays and a cell biological assay of
PC12 cell differentiation. Our preferred interpretation is that
these observations are related, but it is formally possible that
they represent separate phenomena, i.e. the linker domain
regulates Ha-Ras microdomain association and also has a sep-
arate direct role in regulating effector interactions. The results
with myristoylated Ha-Ras, however, argue against this alter-
native hypothesis. N-myristoylated plasma membrane-local-
ized Ha-RasG12V is confined to lipid rafts, in this case because
the additional saturated fatty acid facilitates partitioning into
liquid-ordered membrane. The linker domain is intact in my-
ristoylated Ha-Ras; therefore the observed defective effector
function is most likely due to raft association.
Although Raf activation was compromised by confinement to
lipid rafts, downstream activation of MEK and MAPK was
apparently unaffected. A similar observation was made re-
cently by Chen and Resh (34), who targeted Raf to lipid rafts
using the Src or Fyn N-terminal motifs or to disordered mem-
brane using the Ki-Ras C-terminal targeting motifs. Raf kinase
activity per se was not assayed in their study, but all three Raf
constructs activated MEK and Erk with equal efficiency. A
complete explanation of these data is not possible at the pres-
ent time, although it has been demonstrated by others that the
correct coordination of activity within the Raf/MEK/Erk cas-
cade is critically dependent on raft structure and function (35).
In addition, it has recently been proposed that internalization
of RasRaf complexes may be required for efficient activation of
MEK and Erk (36). If so, the data in Fig. 3A could be rational-
ized by speculating that raft-associated Raf is more extensively
endocytosed than Raf associated with disordered membrane.
Notwithstanding the phospho-MEK and phospho-Erk results,
the PC12 experiments clearly show that the biological activity
of Ha-Ras correlates closely with raft dissociation.
Suppression of the S17N dominant negative phenotype in
the context of all five linker domain deletions or alanine sub-
stitutions demonstrates that the interaction of RasGEFs with
membrane-associated Ha-Ras is critically dependent on the
integrity of the linker domain. Unlike the requirements for
normal effector function, we cannot safely conclude that any of
the Ha-Ras linker domain acts simply as a spacer element for
RasGEF binding given that deleted and alanine-substituted
proteins were equally compromised. In a co-crystal of the Sos1
catalytic domain with Ha-Ras, the C terminus of Ha-Ras is
orientated away from the contact surfaces (37, 38). However,
the C-terminal 25 amino acids of Ha-Ras and the non-catalytic
domains of Sos-1 were absent from the solved protein complex,
so it remains possible that some direct interaction between the
Ha-Ras HVR and Sos1 is important for their efficient func-
tional interaction at the plasma membrane. Indeed we have
shown previously that prenylated Ras is a better substrate for
Sos1 than unmodified Ras in vitro (39), observations that also
demonstrate that C-terminal Ras epitopes influence N-termi-
nal protein/protein interactions.
Although there was good correlation between the two assays
of RasGEF/Ha-Ras interaction with respect to three of the HVR
linker domains mutants (Fig. 6, A and B), this was not the case
for H1ala and H1. The increased basal and Sos1-stimulated
GTP loading is at variance with the reduced levels expected, as
seen with H2ala and H2. One explanation for these results
is that the ability of GAP to interact with membrane-associated
H1ala and H1 is also compromised. If so, then despite a
compromised interaction with Sos1, as demonstrated by the
S17N toxicity assay result, H1ala and H1 proteins that are
wild type at codon Gly12 would still accumulate in the GTP-3 J. Clyde-Smith and J. F. Hancock, unpublished observations.
The Hypervariable Region and Ha-Ras Function 277
 at UQ Library on October 16, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
bound state. Wild type H1ala and H1, however, do not drive
differentiation of PC12 cells (data not shown), presumably be-
cause, although GTP-loaded, their effector interactions are also
compromised to the same extent as the cognate G12V-substi-
tuted proteins. The interaction of p120GAP with the Ha-Ras
linker domain mutants is currently being investigated.
In summary, we have shown here that the HVR linker do-
main modulates the effector, GEF, and possibly GAP interac-
tions of plasma membrane-localized Ha-Ras. There are still
some unanswered questions as to how the linker domain me-
diates these effects, but it is clearly essential for normal Ha-
Ras biological function.
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